Products

  1. Home
  2. Products
  3. Gastrointestinal
  4. IDKmonitor® Vedolizumab Free ADA ELISA

IDKmonitor® Vedolizumab Free ADA ELISA

Item #: KR9648 Categories: ,

$946.00

Available with Lead Time!

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 50 µl
Species: Human
Incubation time: 3h 10m
Size: 96 wells
Regulatory Status: For research use only in the U.S.
Kit Manual: Download

The IDKmonitor® Vedolizumab Free ADA ELISA is intended for the determination of free human antibodies against vedolizumab (e.g., ENTYVIO®) in EDTA plasma and serum.

For research use only. Not for use in diagnostic procedures.

For Laboratory Professional Use Only.

This is the RUO version of Immundiagnostik part number K 9648.

Browse our other Vedolizumab Kits.

Test Principle of the IDKmonitor® Vedolizumab Free ADA ELISA

The IDKmonitor® Vedolizumab Free ADA ELISA is designed for the determination of free antibodies against vedolizumab (e. g. ENTYVIO®).

In the first incubation step, the free anti-vedolizumab antibodies from the sample are bound to the vedolizumab F(ab) fragments coated on the plate. After a washing step to remove all unbound substances, the detection antibody (biotinylated therapy antibody) is added. After another washing step, the streptavidin conjugate is added to detect the anti-vedolizumab antibodies. After another washing step, the solid phase is incubated with the tetramethylbenzidine (TMB) substrate. An acidic stop solution is then added.

The color converts to yellow. The absorbance of the color compound is determined photometrically at 450 nm. The intensity of the color is directly proportional to the amount of bound anti-vedolizumab antibodies.
(e.g. ENTYVIO®) from the sample. The results are evaluated by a cut-off control.

 

Additional information

Weight 35.5 oz
Dimensions 6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!